Ponatinib

Search with Google Search with Bing

Information
Drug Name
Ponatinib
Description
Entry(CIViC)
33
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
acute myeloid leukemia FLT3 p.Asp835Tyr (p.D835Y)
( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y)
( ENST00000241453.12 ) 		D Predictive Supports Resistance Somatic 3 23430109 Detail
endometrial cancer FGFR2 MUTATION FGFR2 MUTATION D Predictive Supports Sensitivity/Response Somatic 3 26574622 Detail
Ewing sarcoma of bone FGFR1 p.Asn542Lys (p.N542K)
( ENST00000326324.10, ENST00000683815.1, ENST00000684654.1, ENST00000703405.1, ENST00000532791.5, ENST00000335922.9, ENST00000341462.9, ENST00000356207.9, ENST00000397091.9, ENST00000397103.5, ENST00000397108.8, ENST00000397113.6, ENST00000425967.8, ENST00000447712.7, ENST00000683765.1 ) FGFR1 p.Asn542Lys (p.N542K)
( ENST00000326324.10, ENST00000335922.9, ENST00000341462.9, ENST00000356207.9, ENST00000397091.9, ENST00000397103.5, ENST00000397108.8, ENST00000532791.5, ENST00000397113.6, ENST00000425967.8, ENST00000447712.7, ENST00000683765.1, ENST00000683815.1, ENST00000684654.1, ENST00000703405.1 ) 		E Predictive Supports Sensitivity/Response Somatic 2 26179511 Detail
Ewing sarcoma of bone FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		D Predictive Supports Sensitivity/Response N/A 3 26179511 Detail
chronic myeloid leukemia ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) B Predictive Supports Sensitivity/Response Somatic 4 23190221 Detail
estrogen-receptor positive breast cancer FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		D Predictive Supports Sensitivity/Response Somatic 3 22238366 Detail
myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 PDGFRA FIP1L1-PDGFRA D Predictive Supports Sensitivity/Response 3 24407160 Detail
myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 PDGFRA FIP1L1-PDGFRA T674I D Predictive Supports Sensitivity/Response Somatic 3 24407160 Detail
cholangiocarcinoma FGFR2 FGFR2-MGEA5 C Predictive Supports Sensitivity/Response Somatic 2 24550739 Detail
cholangiocarcinoma FGFR2 FGFR2-TACC3 C Predictive Supports Sensitivity/Response Somatic 3 24550739 Detail
gastrointestinal stromal tumor KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT P551_E554delPMYE KIT P551_E554delPMYE D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Resistance Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000690543.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 25239608 Detail
gastrointestinal stromal tumor KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Sensitivity/Response Somatic 3 25239608 Detail
chronic myeloid leukemia ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) D Predictive Supports Sensitivity/Response Somatic 3 24236021 Detail
chronic myeloid leukemia ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) B Predictive Supports Sensitivity/Response Somatic 5 25349473 Detail
lung cancer FGFR1 EXPRESSION FGFR1 EXPRESSION D Predictive Supports Sensitivity/Response N/A 4 24771645 Detail
acute myeloid leukemia FLT3 ITD FLT3 ITD D Predictive Supports Sensitivity/Response Somatic 5 21482694 Detail
acute myeloid leukemia KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 21482694 Detail
acute myeloid leukemia FGFR1 FGFR1OP2-FGFR1 D Predictive Supports Sensitivity/Response Somatic 2 21482694 Detail
gastrointestinal stromal tumor KIT V560_L576DEL KIT V560_L576DEL D Predictive Does Not Support Sensitivity/Response Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Resistance Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Resistance Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Thr671Ile (p.T671I)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Thr671Ile (p.T671I)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Resistance Somatic 5 25239608 Detail
acute lymphoblastic leukemia ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) D Predictive Does Not Support Resistance Somatic 3 25686603 Detail
chronic myeloid leukemia ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) D Predictive Does Not Support Resistance Somatic 3 25686603 Detail
chronic myeloid leukemia ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V D Predictive Supports Sensitivity/Response Somatic 2 25686603 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
An in-vitro saturation mutagenesis screen of 50 in... FLT3 FLT3 p.Asp835Tyr (p.D835Y)
( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y)
( ENST00000241453.12 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Preclinical study in endometrial cancer cell lines... FGFR2 FGFR2 MUTATION FGFR2 MUTATION Sensitivity true CIViC Evidence detail
116 Ewing's sarcoma tumor samples were analyzed in... FGFR1 FGFR1 p.Asn542Lys (p.N542K)
( ENST00000326324.10, ENST00000683815.1, ENST00000684654.1, ENST00000703405.1, ENST00000532791.5, ENST00000335922.9, ENST00000341462.9, ENST00000356207.9, ENST00000397091.9, ENST00000397103.5, ENST00000397108.8, ENST00000397113.6, ENST00000425967.8, ENST00000447712.7, ENST00000683765.1 ) FGFR1 p.Asn542Lys (p.N542K)
( ENST00000326324.10, ENST00000335922.9, ENST00000341462.9, ENST00000356207.9, ENST00000397091.9, ENST00000397103.5, ENST00000397108.8, ENST00000532791.5, ENST00000397113.6, ENST00000425967.8, ENST00000447712.7, ENST00000683765.1, ENST00000683815.1, ENST00000684654.1, ENST00000703405.1 ) 		Sensitivity true CIViC Evidence detail
116 Ewing's sarcoma tumor samples were analyzed in... FGFR1 FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		Sensitivity true CIViC Evidence detail
Study describes a phase 1 clinical trial of ponati... ABL1 ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) Sensitivity true CIViC Evidence detail
In MDA-MB-134 cells (ER-positive breast cancer cel... FGFR1 FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		Sensitivity true CIViC Evidence detail
In a FIP1L1-PDGFRA positive eosinophil cell line g... PDGFRA PDGFRA FIP1L1-PDGFRA Sensitivity true CIViC Evidence detail
Ba/F3 cells expressing two clinically relevant, im... PDGFRA PDGFRA FIP1L1-PDGFRA T674I Sensitivity true CIViC Evidence detail
In a single patient with this fusion in intrahepat... FGFR2 FGFR2 FGFR2-MGEA5 Sensitivity true CIViC Evidence detail
In a 43 year old female patient with this fusion i... FGFR2 FGFR2 FGFR2-TACC3 Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT P551_E554delPMYE KIT P551_E554delPMYE Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
A preclinical study tested the effect of a tyrosin... KIT KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
In an in vitro kinase study, a KIT V559D primary a... KIT KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000690543.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity false CIViC Evidence detail
Molecular dynamics simulations and calculated solv... ABL1 ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) Sensitivity true CIViC Evidence detail
Ponatinib has shown to be effective in patients wi... ABL1 ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) Sensitivity true CIViC Evidence detail
Preclinical evidence (in-vitro) for predictive val... FGFR1 FGFR1 EXPRESSION FGFR1 EXPRESSION Sensitivity true CIViC Evidence detail
In a preclinical trial, multiple experiments testi... FLT3 FLT3 ITD FLT3 ITD Sensitivity true CIViC Evidence detail
In this preclinial trial, the AML cell line Kasumi... KIT KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In this preclinial trial, the AML cell line KG1 wi... FGFR1 FGFR1 FGFR1OP2-FGFR1 Sensitivity true CIViC Evidence detail
In the patient-derived cell line GIST430 harboring... KIT KIT V560_L576DEL KIT V560_L576DEL Sensitivity false CIViC Evidence detail
In an in vitro kinase study, a KIT V560G primary a... KIT KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
The GIST882 patient derived cell line expressing K... KIT KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
A preclinical study was done in order to test the ... KIT KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Ponatinib possesses potent activity against A829P ... KIT KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Several preclinical studies tested the effects of ... KIT KIT p.Thr671Ile (p.T671I)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Thr671Ile (p.T671I)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Bone marrow mononuclear cells (BM MNCs) were isola... ABL1 ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) Resitance or Non-Reponse false CIViC Evidence detail
Bone marrow mononuclear cells (BM MNCs) were isola... ABL1 ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) Resitance or Non-Reponse false CIViC Evidence detail
Bone marrow mononuclear cells isolated from a chro... ABL1 ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT04591431 Active, not recruiting Phase 2 The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy October 7, 2020 June 2025
NCT04501614 Active, not recruiting Phase 1/Phase 2 A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia February 24, 2021 January 4, 2027
NCT03589326 Active, not recruiting Phase 3 A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia October 4, 2018 July 31, 2027
NCT03709017 Active, not recruiting Iclusig PMS in CML or Ph+ALL Patients August 7, 2018 June 2023
NCT03147612 Active, not recruiting Phase 2 Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia February 8, 2018 February 28, 2025
NCT02467270 Active, not recruiting Phase 2 Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses June 30, 2015 June 1, 2024
NCT04233346 Active, not recruiting Phase 2 The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation July 9, 2020 December 31, 2025
NCT01424982 Active, not recruiting Phase 2 Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia October 5, 2011 October 31, 2025
NCT04188405 Active, not recruiting Phase 2 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia May 17, 2020 September 1, 2024
NCT04070443 Active, not recruiting Phase 2 Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase November 13, 2019 June 1, 2029
NCT01592136 Approved for marketing Expanded Access Program of Ponatinib
NCT05286528 Completed Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database November 18, 2020 January 31, 2022
NCT01207440 Completed Phase 2 Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) September 30, 2010 January 17, 2019
NCT01641107 Completed Phase 2 Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. December 4, 2014 September 30, 2021
NCT01813734 Completed Phase 2 Ponatinib in Advanced NSCLC w/ RET Translocations September 2013 August 2018
NCT01874665 Completed Phase 2 A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor June 5, 2013 July 31, 2016
NCT01935336 Completed Phase 2 Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers September 24, 2013 November 2017
NCT02478164 Completed Phase 2 Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma July 13, 2015 May 9, 2018
NCT00660920 Completed Phase 1 Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies June 2008 May 2016
NCT01549548 No longer available Compassionate Use Ponatinib
NCT04688983 Not yet recruiting Phase 2 Study in Adult Ph-positive ALL January 2021 January 2026
NCT06175702 Not yet recruiting Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL December 25, 2023 December 25, 2030
NCT06390306 Not yet recruiting The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP May 1, 2024 December 1, 2026
NCT06207123 Not yet recruiting Phase 1/Phase 2 A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) April 1, 2025 December 1, 2026
NCT03263572 Recruiting Phase 2 Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia November 29, 2017 November 30, 2025
NCT03895671 Recruiting Phase 2 PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS June 19, 2019 December 1, 2024
NCT03934372 Recruiting Phase 1/Phase 2 Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors January 29, 2020 January 4, 2025
NCT06061094 Recruiting Phase 2 Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT July 14, 2023 July 1, 2029
NCT05268003 Recruiting Phase 2 A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia June 7, 2022 October 5, 2026
NCT04475731 Recruiting Phase 2 Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse May 4, 2021 November 2024
NCT04747912 Recruiting Phase 2 Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) March 2, 2021 May 1, 2026
NCT05306301 Recruiting Phase 2 Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients October 5, 2022 July 1, 2028
NCT01620216 Terminated Phase 2 Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia May 11, 2012 April 30, 2017
NCT01838642 Terminated Phase 2 Ponatinib for Advanced Medullary Thyroid Cancer March 2013 January 2016
NCT03807479 Terminated Phase 2 Study in Patients With Chronic Leukemia December 11, 2018 August 31, 2023
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT01761747 Terminated Phase 2/Phase 3 Ponatinib for Squamous Cell Lung and Head and Neck Cancers January 2013 June 2014
NCT01650805 Terminated Phase 3 Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) June 2012 October 2013
NCT01570868 Terminated Phase 2 Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) April 2012 May 2016
NCT02448095 Terminated Retrospective Evaluation of CML Patients in the National Compassionate Program December 22, 2015 July 17, 2018
NCT02398825 Unknown status Phase 2 Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib June 23, 2016 February 2023
NCT04043676 Unknown status Phase 2 Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia April 30, 2019 April 30, 2023
NCT02776605 Unknown status Phase 2 Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia June 2016 August 2023
NCT04845035 Withdrawn Phase 2 Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia January 2024 January 2029
NCT01888562 Withdrawn N/A Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma January 2016 July 2023
NCT03838692 Withdrawn Phase 2 Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer July 26, 2019 June 14, 2021
NCT02829840 Withdrawn Phase 1/Phase 2 Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) September 2016